Vydura (rimegepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist used for acute treatment of cluster headaches. By blocking CGRP receptors, it inhibits the inflammatory cascade associated with cluster headache pathogenesis, reducing pain intensity and duration. The medication provides targeted neurological intervention with a relatively rapid onset of action and favorable tolerability profile.